PharmaTimesNews & Politicsnews

MimiVax and Roswell Park open phase 2 trial of SurVaxM for metastatic neuroendocrine tumours

Tuesday, May 5, 2026John PinchingView original

Study expands evaluation of survivin‑targeting vaccine

Read the full article on the original site.

Read Full Article